Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Despite Ranbaxy Setback, Indian Cos' Drug Research Stays on Course (India)

This article was originally published in PharmAsia News

Executive Summary

The malaria drug industry faced a major setback following the withdrawal of funding by the Medicines for Malaria Venture (MMV) from an attempt by Ranbaxy Ltd. to develop a new antimalarial treatment. Although Ranbaxy plans to go forward, without funding some are skeptical of the drug's chances. However, two other Indian companies also have promising antimalarial drugs in development. Ipca Laboratories Ltd. leads the pack with four prospects. Two of these molecules are being developed with the support of the Central Drug Research Institute and are currently in preclinical or phase I trials. A third molecule, developed by the Indian Institute of Science, is also in preclinical trials. Ipca's fourth drug in the works is just a new dosage of an older treatment. The fifth drug is being tested by Unimark Pharma Ltd. with the support of the MMV. All five drugs are based on some combination of arteminsinin, a Chinese herb. (Click here for more

You may also be interested in...



China Preps For First COVID Vaccine Roll-Outs

Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers. 

QUOTED. 3 December. Jessica Schubel.

A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.

Bukwang Speeds Lead Asset As It Eyes Danish Operation's Listing

Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel